[go: up one dir, main page]

WO2025188598A1 - Dispositif injecteur - Google Patents

Dispositif injecteur

Info

Publication number
WO2025188598A1
WO2025188598A1 PCT/US2025/018089 US2025018089W WO2025188598A1 WO 2025188598 A1 WO2025188598 A1 WO 2025188598A1 US 2025018089 W US2025018089 W US 2025018089W WO 2025188598 A1 WO2025188598 A1 WO 2025188598A1
Authority
WO
WIPO (PCT)
Prior art keywords
deformable element
configuration
needle cover
delivery device
medicament delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
PCT/US2025/018089
Other languages
English (en)
Other versions
WO2025188598A8 (fr
Inventor
Alexander Hee-Hanson
Thomas LEVER
Michael Parrott
Robert Wilson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genzyme Corp
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US18/594,643 external-priority patent/US12274874B1/en
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of WO2025188598A1 publication Critical patent/WO2025188598A1/fr
Publication of WO2025188598A8 publication Critical patent/WO2025188598A8/fr
Pending legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M5/2033—Spring-loaded one-shot injectors with or without automatic needle insertion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/20—Automatic syringes, e.g. with automatically actuated piston rod, with automatic needle injection, filling automatically
    • A61M2005/2006—Having specific accessories
    • A61M2005/2013—Having specific accessories triggering of discharging means by contact of injector with patient body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178—Syringes
    • A61M5/31—Details
    • A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
    • A61M5/3205—Apparatus for removing or disposing of used needles or syringes, e.g. containers; Means for protection against accidental injuries from used needles
    • A61M5/321—Means for protection against accidental injuries by used needles
    • A61M5/3243—Means for protection against accidental injuries by used needles being axially-extensible, e.g. protective sleeves coaxially slidable on the syringe barrel
    • A61M5/326—Fully automatic sleeve extension, i.e. in which triggering of the sleeve does not require a deliberate action by the user
    • A61M2005/3267—Biased sleeves where the needle is uncovered by insertion of the needle into a patient's body
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/58—Means for facilitating use, e.g. by people with impaired vision
    • A61M2205/581—Means for facilitating use, e.g. by people with impaired vision by audible feedback

Definitions

  • This application relates to an injector device for delivery of a medicament, particularly to an auto-injector device.
  • Injector devices are used to deliver a range of medicaments. In an auto-injector device, some or all of the actions required to use the injector device in administering medicament to a user are automated.
  • an auto-injector device having a needle cover which is axially movable to cover and uncover a needle, with the needle cover being biased by a spring to extend over the needle.
  • the user presses the needle cover against an injection site, against the force of the spring, to push the needle cover into the housing and to uncover the needle which is pushed into the injection site.
  • Medicament is automatically dispensed from the needle via an automated mechanism.
  • a user typically holds the needle cover in a holding position for a predetermined period of time, to ensure that the correct dose of medicament is dispensed from the device, before removing the device from the injection site.
  • a first aspect of this disclosure provides a medicament delivery device for reducing a force required to activate the medicament delivery device, wherein the medicament delivery device comprises: a needle for injecting medicament into a user, the needle disposed at a distal end of the medicament delivery device; a needle cover and a body, wherein the needle cover is axially movable relative to the body between an initial position, in which the needle cover covers the needle, and an activated position for dispensing medicament from the medicament delivery device, wherein in the activated position the needle protrudes from the distal end of the needle cover; and a carrier configured to support a pre-filled syringe, wherein the carrier is disposed within the needle cover and comprises a deformable element configured to change from a first configuration in which the deformable element is engaged with the needle cover to a second configuration in which the deformable element is not engaged with the needle cover.
  • the deformable element may have the first configuration when the needle cover is in the initial position and may have the second configuration when the needle cover is in an intermediate position, between the initial position and the activated position.
  • Movement of the needle cover from the initial position to the intermediate position may cause the deformable element to be deformed from the first configuration to the second configuration.
  • the needle cover may comprise a cooperating element and wherein the deformable element may be configured to engage with the cooperating element in the first configuration and to be disengaged from the cooperating element in the second configuration.
  • the cooperating element may comprise an aperture, a recess, a ridge or a frictional surface.
  • the cooperating element may comprises a slot and the deformable element is configured to abut an edge of the slot in the first configuration.
  • Movement of the needle cover proximally from the initial position may cause the deformable element to disengage from the slot.
  • the deformable element may be configured to produce a sound when deforming from the first configuration to the second configuration.
  • the deformable element may be configured to produce a vibration when deforming from the first configuration to the second configuration.
  • the deformable element may be configured to be deformed from a first shape in the first configuration to a second shape in the second configuration.
  • the deformable element may be configured: to have a convex shape which protrudes from the carrier towards the needle cover in the first configuration; and to have a concave shape which curves away from the needle cover in the second configuration.
  • the deformable element may be in a stressed state when in the second configuration.
  • the deformable element may be configured to be permanently retained in the second configuration by a latching member.
  • the deformable element may be configured to break in the second configuration.
  • the deformable element may comprise a flexible arm with a stress concentrating region and may be configured to break at the stress concentrating region when the flexible arm is deflected by the needle cover.
  • the deformable element may be in a stressed state when in the first configuration.
  • the medicament delivery device of the first aspect may comprise multiple deformable elements.
  • the needle cover may comprise multiple cooperating elements and each of the multiple deformable elements may be configured to engage with a respective one of the multiple cooperating elements in the first configuration and to be disengaged from the respective cooperating element in the second configuration.
  • the deformable element may comprise a flexible arm and a protrusion disposed on a free end of the flexible arm. A distal facing edge of the protrusion may be bevelled.
  • the medicament delivery device may further comprise a spring configured to exert a spring force which biases the needle cover axially, towards the distal end of the medicament delivery device.
  • the medicament delivery device may further comprise the pre-filled syringe.
  • a second aspect of this disclosure provides a medicament delivery device for reducing a force required to activate the medicament delivery device, wherein the medicament delivery device comprises: a needle for injecting medicament into a user, the needle disposed at a distal end of the medicament delivery device; a needle cover and a body, wherein the needle cover is configured to be moved in a proximal direction into the body of the medicament delivery device to expose the needle; a pre-filled syringe carrier, wherein the pre-filled syringe carrier is disposed within the needle cover and comprises a deformable element, wherein the deformable element is configured: prior to activation of the medicament delivery device, to have a first configuration in which the deformable element is engaged with the needle cover; during an initial portion of an activation movement of the needle cover, to be forced to deform into a second configuration by movement of the needle cover, wherein the deformable element is not engaged with the needle cover when in the second configuration; and to remain in the second configuration for the remainder of the activation movement of the needle cover so
  • the deformable element may deform permanently into the second configuration.
  • the deformable element may be configured to be deformed from a first shape in the first configuration to a second shape in the second configuration.
  • the deformable element may be configured: to have a convex shape which protrudes from the carrier towards the needle cover in the first configuration; an to have a concave shape which curves away from the needle cover in the second configuration.
  • the deformable element may be configured to be permanently retained in the second configuration by a latching member.
  • the deformable element may be in a stressed state when in the first configuration.
  • the deformable element may be configured to break in the second configuration.
  • Figure 1 A shows an injector device with a cap attached
  • Figure 1 B shows the injector device of Figure 1 A with the cap removed
  • Figure 2A shows a simplified view of an injector device prior to use
  • Figure 2B shows a view of the device of Figure 2A with injector device in the holding position
  • Figure 3A shows a device in a pre-use state
  • Figure 3B shows the device at the start of an activation movement
  • Figure 3C shows the device in a mid-activation state
  • Figure 3D shows the device in an activated state
  • Figure 4A is a perspective view of a cross section of the device in the initial state of Figure 3A;
  • Figure 4B is a perspective view of a cross section of the device in the mid-activation state of Figure 3C;
  • Figure 5A shows a medicament delivery device according to a first embodiment in an initial state
  • Figure 5B shows the medicament delivery device of the first embodiment at the start of an activation movement
  • Figure 5C shows the medicament delivery device of the first embodiment in an activated state
  • Figure 6A is a perspective view of a cross section of the medicament delivery device of the first embodiment in the initial state of Figure 5A;
  • Figure 6B is a perspective view of a cross section of the medicament delivery device of the first embodiment at the start of an activation movement (equivalent to Figure 5B);
  • Figure 7A shows a medicament delivery device according to a second embodiment in an initial state
  • Figure 7B shows the medicament delivery device of the second embodiment at the start of an activation movement
  • Figure 7C shows the medicament delivery device of the second embodiment in an activated state
  • Figure 8A shows a medicament delivery device according to a third embodiment in an initial state
  • Figure 8B shows the medicament delivery device of the second embodiment in an activated state
  • Figure 8C shows a close-up of a deformable element of the third embodiment in a first configuration
  • Figure 8D shows a close-up of a deformable element of the third embodiment in a second configuration
  • Figure 9A shows portions of a medicament delivery device according to a fourth embodiment with a deformable element in a first configuration
  • Figure 9B shows portions of a medicament delivery device according to a fourth embodiment with a deformable element in a second configuration
  • Figure 10 is a force profile graph illustrating the force profile of a first device and the medicament delivery devices according to the first to fourth embodiments.
  • a drug delivery device may be configured to inject a medicament into a patient.
  • delivery could be sub-cutaneous, intra-muscular, or intravenous.
  • Such a device could be operated by a patient or care-giver, such as a nurse or physician, and can include various types of safety syringe, pen-injector, or auto-injector.
  • the device can include a cartridge-based system that requires piercing a sealed ampule before use. Volumes of medicament delivered with these various devices can range from about 0.5 ml to about 2 ml.
  • Yet another device can include a large volume device (“LVD”) or patch pump, configured to adhere to a patient’s skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a “large’’ volume of medicament (typically about 2 ml to about 10 ml).
  • LLD large volume device
  • patch pump configured to adhere to a patient’s skin for a period of time (e.g., about 5, 15, 30, 60, or 120 minutes) to deliver a “large’’ volume of medicament (typically about 2 ml to about 10 ml).
  • the presently described devices may also be customized in order to operate within required specifications.
  • the device may be customized to inject a medicament within a certain time period (e.g., about 3 to about 20 seconds for auto-injectors, and about 10 minutes to about 60 minutes for an LVD).
  • Other specifications can include a low or minimal level of discomfort, or to certain conditions related to human factors, shelf-life, expiry, biocompatibility, environmental considerations, etc.
  • Such variations can arise due to various factors, such as, for example, a drug ranging in viscosity from about 3 cP to about 50 cP. Consequently, a drug delivery device will often include a hollow needle ranging from about 25 to about 31 Gauge in size. Common sizes are 27 and 29 Gauge.
  • the delivery devices described herein can also include one or more automated functions.
  • one or more of needle insertion, medicament injection, and needle retraction can be automated.
  • Energy for one or more automation steps can be provided by one or more energy sources.
  • Energy sources can include, for example, mechanical, pneumatic, chemical, or electrical energy.
  • mechanical energy sources can include springs, levers, elastomers, or other mechanical mechanisms to store or release energy.
  • One or more energy sources can be combined into a single device.
  • Devices can further include gears, valves, or other mechanisms to convert energy into movement of one or more components of a device.
  • the one or more automated functions of an auto-injector may each be activated via an activation mechanism.
  • Such an activation mechanism can include one or more of a button, a lever, a needle sleeve, or other activation component.
  • Activation of an automated function may be a one-step or multi-step process. That is, a user may need to activate one or more activation components in order to cause the automated function. For example, in a one-step process, a user may depress a needle sleeve against their body in order to cause injection of a medicament. Other devices may require a multi-step activation of an automated function. For example, a user may be required to depress a button and retract a needle shield in order to cause injection.
  • activation of one automated function may activate one or more subsequent automated functions, thereby forming an activation sequence.
  • activation of a first automated function may activate at least two of needle insertion, medicament injection, and needle retraction.
  • Some devices may also require a specific sequence of steps to cause the one or more automated functions to occur.
  • Other devices may operate with a sequence of independent steps.
  • Some delivery devices can include one or more functions of a safety syringe, pen-injector, or auto-injector.
  • a delivery device could include a mechanical energy source configured to automatically inject a medicament (as typically found in an autoinjector) and a dose setting mechanism (as typically found in a pen-injector).
  • an exemplary drug delivery device 10 is shown in Figs. 1A & 1B.
  • Device 10 as described above, is configured to inject a medicament into a patient’s body.
  • Device 10 includes a housing 11 which typically contains a reservoir containing the medicament to be injected (e.g., a syringe) and the components required to facilitate one or more steps of the delivery process.
  • Device 10 can also include a cap assembly 12 that can be detachably mounted to the housing 11. Typically a user removes cap 12 from housing 11 before device 10 can be operated.
  • housing 11 is substantially cylindrical and has a substantially constant diameter along the longitudinal axis X.
  • the housing 11 has a distal region 20 and a proximal region 21 .
  • the term “distal” refers to a location that is relatively closer to a site of injection, and the term “proximal” refers to a location that is relatively further away from the injection site.
  • Device 10 can also include a needle sleeve 13 coupled to housing 11 to permit movement of sleeve 13 relative to housing 11.
  • sleeve 13 can move in a longitudinal direction parallel to longitudinal axis X.
  • movement of sleeve 13 in a proximal direction can permit a needle 17 to extend from distal region 20 of housing 11 .
  • Insertion of needle 17 can occur via several mechanisms.
  • needle 17 may be fixedly located relative to housing 11 and initially be located within an extended needle sleeve 13. Proximal movement of sleeve 13 by placing a distal end of sleeve 13 against a patient’s body and moving housing 11 in a distal direction will uncover the distal end of needle 17. Such relative movement allows the distal end of needle 17 to extend into the patient’s body.
  • Such insertion is termed “manual” insertion as needle 17 is manually inserted via the patient’s manual movement of housing 11 relative to sleeve 13.
  • buttons 22 are located at a proximal end of housing 11 .
  • button 22 could be located on a side of housing 11.
  • a drive spring is under compression before device 10 is activated.
  • a proximal end of the drive spring can be fixed within proximal region 21 of housing 11 , and a distal end of the drive spring can be configured to apply a compressive force to a proximal surface of piston 23.
  • at least part of the energy stored in the drive spring can be applied to the proximal surface of piston 23. This compressive force can act on piston 23 to move it in a distal direction. Such distal movement acts to compress the liquid medicament within the syringe, forcing it out of needle 17.
  • needle 17 can be retracted within sleeve 13 or housing 11. Retraction can occur when sleeve 13 moves distally as a user removes device 10 from a patient’s body. This can occur as needle 17 remains fixedly located relative to housing 11 . Once a distal end of sleeve 13 has moved past a distal end of needle 17, and needle 17 is covered, sleeve 13 can be locked. Such locking can include locking any proximal movement of sleeve 13 relative to housing 11. Another form of needle retraction can occur if needle 17 is moved relative to housing 11. Such movement can occur if the syringe within housing 11 is moved in a proximal direction relative to housing 11.
  • This proximal movement can be achieved by using a retraction spring, located in distal region 20.
  • a compressed retraction spring when activated, can supply sufficient force to the syringe to move it in a proximal direction.
  • any relative movement between needle 17 and housing 11 can be locked with a locking mechanism.
  • button 22 or other components of device 10 can be locked as required.
  • Figures 2A and 2B show a simplified view of a device 110 having a needle cover 113 which is axially movable to cover and uncover the needle 117.
  • the needle cover 113 is biased by a spring 104 to extend over the needle 117.
  • Figure 2A shows the device before use, in which the needle cover 113 is exposed out of the end of the device body 103 and covers the needle 117.
  • a force can be applied by a user against a spring force 125 to move the needle cover 113 from the position shown in Figure 2A towards a holding position shown in Figure 2B, and a holding force 120 can be applied to maintain the needle cover in the holding position.
  • the user presses the needle cover 113 against an injection site 115 to push the needle cover 113 at least partially into the device body 103.
  • the exposed needle 117 is pushed into the injection site 115.
  • medicament is automatically dispensed from the needle 117 via an automated mechanism.
  • a user typically holds the needle cover 113 in the holding position for a predetermined period of time, to ensure that the correct dose of medicament is dispensed from the device 110, before removing the device from the injection site 115.
  • the spring force 125 against which the user must applies a force to move the needle cover 113 is one component of the “activation force” of the device 110.
  • the activation force refers to the force or force profile that the user exerts on the device 110 to move the needle cover 113 from the position shown in Figure 2A to the position shown in Figure 2B. If this force or force profile is not well balanced, it can lead to difficulty in activating the device 100 for some users, or increase the pain or anxiety associated with using the device.
  • Figures 3A to 3D show further details of the operation of the device 110. These Figures each show a cross section of the one half of the device 110 during various stages of activation of the device.
  • Figure 3A shows the device in a pre-use state, may also be called an initial state or initial position.
  • the needle cover 113 covers the needle 117 in this position.
  • a spring may bias the needle cover 113 distally so that it extends over the needle 117.
  • the device 110 also comprises a carrier 300, which supports a pre-filled syringe 302.
  • the needle 117 is in fluid communication with the pre-filled syringe 302 and extends from the distal end of the prefilled syringe 302.
  • the carrier 300 comprises a resilient member 304 which takes the form of a flexible arm which extends axially (or longitudinally) and which has a protrusion 306 on the free end of the flexible arm.
  • the protrusion 306 extends radially from the flexible arm to engage with a first slot in the needle cover 113.
  • the carrier 300 may comprise two or more resilient members 304.
  • two resilient members 304 may be disposed opposite each other on the carrier 300 and may engage with corresponding slots in the needle cover 113. Having the resilient member 304 engage a slot in the needle cover 113 in this initial position may prevent axial travel of the needle cover 113 during assembly of the device 110 and may help to prevent inadvertent activation of the device 110.
  • Figure 3B shows the device 110 at the start of an activation movement.
  • a distal force is applied via the body 103 while the needle cover 113 is placed against the user’s skin, causing the needle cover 113 to move proximally into the device 110.
  • the resilient member 304 is deflected and exits the first slot in the needle cover 113.
  • the resilient member 304 abuts an inner surface of the needle cover 113 resulting in a normal force between these components. This leads to a frictional force which resists proximal movement of the needle cover 113 into the device 110 and therefore increases the force required to activate the device 110.
  • Figure 3C shows the device 110 in a mid-activation state. In this position, the needle 117 has protruded from the end of the needle cover 113, but the medicament dispensing mechanism of the device 110 has not yet been triggered. As can be seen, the resilient member 304 is still in a deflected state and still exerts and normal and frictional force on the needle cover 113.
  • Figure 3D shows the device 110 in an activated state. In this position the needle cover 113 is fully displaced into the device 110, the needle 117 protrudes from the end of the needle cover 113 to its maximum extend and the medicament dispensing mechanism of the device 110 is triggered. As can be seen, the resilient member 304 is still in a deflected state and still exerts and normal and frictional force on the needle cover 113.
  • Figure 4A is a perspective view of a cross section of the device 110 in the initial state (as also shown in Figure 3A). In this view it can be seen that the protrusion 306 of the resilient member 304 abuts an end face of the slot 400 in the needle cover 113.
  • the carrier 300 comprises two resilient members 304 on opposite sides and there are two corresponding slots 400 in the needle cover 113.
  • Figure 4B is a perspective view of a cross section of the device 110 in a mid-activation state (as also shown in Figure 3C).
  • the resilient members 304 are deflected, so that the protrusions 306 on the free ends of the flexible arms contact the inner surface of the needle cover 113, increasing the force needed to move the needle cover 113 proximally with respect to the body 103 of the device 110.
  • Figures 5A to 5C shows features of a first embodiment of a medicament delivery device 500, which is also referred to herein as an injector device. These Figures each show a cross section of the one half of the device 500 during various stages of activation of the device.
  • the device has a distal end 502 and a proximal end 504.
  • the device 500 has a needle 506 for injecting medicament into a user at an injection site, a needle cover 508 and a body 510.
  • the body 510 is configured to be gripped by a user.
  • the body 510 forms part of the external surface of the device.
  • the device 500 houses a pre-filled syringe 512.
  • the needle 506 is in fluid communication with the pre-filled syringe 512 and extends from the distal end of the pre-filled syringe 512.
  • the needle cover 508 is axially movable relative to the body 510 between an initial position, shown in Figure 5A, in which the needle cover 508 covers the needle 506, and an activated position, shown in Figure 5C, for dispensing medicament from the device. In the activated position, the needle 506 protrudes from the distal end of the needle cover 508.
  • a spring may exert a spring force against the needle cover 508 which biases the needle cover axially, in the distal direction. A force can be applied by a user against the force of the spring to move the needle cover 508 from the position shown in Figure 5A towards the position shown in Figure 5C.
  • Medicament is dispensed from the medicament delivery device 500 via the needle 506 while the needle cover 508 is in the activated position.
  • An automated mechanism is triggered to start the dispensing of medicament when the needle cover 508 reaches a predetermined axial position within the housing. The predetermined position is located just distally of the activated position.
  • the automated mechanism may comprise a plunger which is automatically released when the needle cover 508 reaches the predetermined axial position. When the plunger is released it moves within the pre-filled syringe to dispense medicament from the syringe through the needle 506.
  • the user removes a cap from the distal end of the medicament delivery device 500.
  • the user presses the needle cover 508 against an injection site to move the needle cover 508 axially relative to the body 510 and to uncover the needle 506.
  • the needle 506 is pushed into the injection site.
  • the automated mechanism is released, and medicament is automatically dispensed from the device via the needle 506.
  • the user holds the needle cover 508 in the activated position while the medicament is dispensed.
  • Figure 5A shows the device 500 in a pre-use state, which may also be called an initial state or initial position.
  • the needle cover 508 covers the needle 506 in this position.
  • the device 500 also comprises a carrier 514, which supports the pre-filled syringe 512.
  • the carrier 514 comprises a deformable element 516 which takes the form of a flexible component.
  • Figure 5A shows the deformable element 516 in a first configuration in which it has a convex shape which protrudes from the carrier 514 towards the needle cover 208.
  • the deformable element 516 comprises a protrusion 518 disposed on the flexible member.
  • the protrusion 518 may be positioned approximately in the centre of the flexible member and directed towards the carrier 514.
  • the flexible member may be an extruded piece of the body of the carrier or a separate element, secured at both ends to the body of the carrier 514.
  • the deformable element 516 may be stressed when in the first configuration. For example, some compression or tension forces may be present in the flexible member. Alternatively, the deformable element 516 may be in a relaxed state in the first configuration.
  • the needle cover has a cooperating element, which may take the form of an aperture, a recess, a ridge or a frictional surface.
  • the deformable element 516 is configured to engage with the cooperating element while in the first configuration and thereby to provide a resistance to proximal movement of the needle cover 508 relative to the carrier 514 and body 510.
  • the cooperating element has the form of a slot (see Figs 6A and 6B) and the deformable element is configured to abut an edge of the slot in the first configuration.
  • the protrusion 518 of the deformable element 516 may abut a proximally facing edge of the slot. A distal facing edge of the protrusion 518 may be beveled, to allow the protrusion 518 to be forced radially inwards when the needle covers is pushed proximally.
  • the carrier 514 may comprise two or more deformable elements 516.
  • two deformable elements 516 may be disposed opposite each other on the carrier 514 and may engage with corresponding slots in the needle cover 508.
  • Figure 5B shows the device 500 at the start of an activation movement.
  • a distal force is applied via the body 510 while the needle cover 508 is placed against the user’s skin, causing the needle cover 508 to move proximally into the device 500.
  • the needle cover 508 In this position, the needle cover 508 is in an intermediate position, between the initial position and the activated position.
  • the deformable element 516 is deflected and exits the slot in the needle cover 508.
  • a normal force is exerted on the protrusion 518 which is forced radially inwards. This causes the flexible member to bend downwards or to become less convex.
  • the main body of the carrier 514 is rigid, compression forces build in the deformable element 516.
  • the deformable element 516 has deflected past a critical position, e.g. beyond a position parallel with the fixed end points of the flexible member, then it snaps into a second configuration, as shown in Figure 5B.
  • the deformable element 516 In this manner, movement of the needle cover 508 from the initial position to the intermediate position causes the deformable element 516 to be deformed from the first configuration to the second configuration.
  • the deformable element 516 In the second configuration, has a concave shape which curves away from the needle cover 508.
  • the deformable element 516 deforms from a first shape in the first configuration to a second shape in the second configuration.
  • the carrier 514 may have an aperture or recess underneath the deformable element 516 to allow room for it to deform into the concave shape.
  • the deformable element 516 may be stressed when in the second configuration. For example, some compression or tension forces may be present in the flexible member. Alternatively, the deformable element 516 may be in a relaxed state in the second configuration.
  • the deformable element 516 may produce a sound when deforming from the first configuration to the second configuration, for example a snapping sound. This may be used to provide feedback to a user or to a sensor within the device 500 or attached to the device 500.
  • the snap sound may be produced by the deformable element 516 itself, or by the deformable element 516 striking an inner surface of a recess in the carrier 514 as it transitions to the second shape.
  • the deformable element 516 may be configured to produce a vibration when deforming from the first configuration to the second configuration. Again, this may be used to provide feedback to a user or to a sensor within the device 500 or attached to the device 500.
  • the vibration may be produced by the deformable element 516 itself, or by the deformable element 516 striking an inner surface of a recess in the carrier 514 as it transitions to the second shape.
  • the deformable element 516 may be referred to as a permanently deformable element or irreversibly deformable element, since in some examples after the element is deformed, the deformation cannot be reversed. In this embodiment, the deformable element 516 does not again assume a convex shape.
  • Figure 5C shows the device 500 in an activated state.
  • the needle cover 508 is fully displaced into the device 500 and is in an activated position.
  • the needle 506 protrudes from the end of the needle cover 508 to its maximum extend and the medicament dispensing mechanism of the device 500 is triggered.
  • the deformable element 516 remains in the second configuration.
  • the deformable element 516 does not exert any normal or friction force on the needle cover 508 in this position or at any point after the intermediate position.
  • the activation force on the needle cover 508 required after the intermediate position is reached is therefore reduced compared to other devices.
  • the movement of the needle cover 508 is reversed, but the deformable element 516 remains in its second configuration.
  • Figure 6A is a perspective view of a cross section of the device 500 in the initial state (as also shown in Figure 5A).
  • the needle cover 508 is in the initial position.
  • the deformable element 516 has a convex shape and a protrusion 518 of the deformable element 516 abuts a proximally facing end face of a slot 600 in the needle cover 508.
  • the slot 600 extends axially and is an aperture through the wall of the needle cover 508.
  • the slot 600 may be provided as a recess in the inner surface of the needle cover 508, which does not extend completely through the wall of the needle cover 508, but which is deep enough to accommodate the protrusion 518 of the deformable element 516 in the first configuration.
  • Figure 6B is a perspective view of a cross section of the device 500 at the start of an activation movement (as also shown in Figure 5B). In this position, the needle cover 508 has moved proximally to an intermediate position and the needle 506 is still shielded by the needle cover 508. The medicament dispensing mechanism of the device 500 has not yet been triggered.
  • the deformable element 516 has a convex shape and is in a second configuration.
  • the deformable element 516 remains in this second configuration for the remainder of the activation movement and throughout device removal. No part of the deformable element 516 is in contact with the needle cover 508 and thus the deformable element 516 does not exert any normal or friction force on the needle cover 508 in this position.
  • the carrier 514 comprises two deformable elements 516 on opposite sides and there are two corresponding slots 600 in the needle cover 508.
  • a symmetrical arrangement of deformable elements 516 may help to ensure a consistent force profile when the device 500 is used.
  • Figures 7A to 7C shows features of a second embodiment of a medicament delivery device 700, which is also referred to herein as an injector device. These Figures each show a cross section of the one half of the device 700 during various stages of activation of the device.
  • the device has a distal end 702 and a proximal end 704.
  • the device 700 has a needle 706 for injecting medicament into a user at an injection site, a needle cover 708 and a body 710.
  • the body 710 is configured to be gripped by a user.
  • the body 710 forms part of the external surface of the device.
  • the device 700 houses a pre-filled syringe 712.
  • the needle 706 is in fluid communication with the pre-filled syringe 712 and extends from the distal end of the pre-filled syringe 712.
  • the needle cover 708 is axially movable relative to the body 710 between an initial position, shown in Figure 7A, in which the needle cover 708 covers the needle 706, and an activated position, shown in Figure 7C, for dispensing medicament from the device. In the activated position, the needle 706 protrudes from the distal end of the needle cover 708.
  • a spring may exert a spring force against the needle cover 708 which biases the needle cover axially, in the distal direction.
  • a force can be applied by a user against the force of the spring to move the needle cover 708 from the position shown in Figure 7A towards the position shown in Figure 7C.
  • Medicament is dispensed from the medicament delivery device 700 via the needle 706 while the needle cover 708 is in the activated position.
  • An automated mechanism is triggered to start the dispensing of medicament when the needle cover 708 reaches a predetermined axial position within the housing. The predetermined position is located just distally of the activated position.
  • the automated mechanism may comprise a plunger which is automatically released when the needle cover 708 reaches the predetermined axial position. When the plunger is released it moves within the pre-filled syringe to dispense medicament from the syringe through the needle 706.
  • the user removes a cap from the distal end of the medicament delivery device 700.
  • the user presses the needle cover 708 against an injection site to move the needle cover 708 axially relative to the body 710 and to uncover the needle 706.
  • the needle 706 is pushed into the injection site.
  • the automated mechanism is released, and medicament is automatically dispensed from the device via the needle 706.
  • the user holds the needle cover 708 in the activated position while the medicament is dispensed.
  • Figure 7A shows the device 700 in a pre-use state, which may also be called an initial state or initial position.
  • the needle cover 708 covers the needle 706 in this position.
  • the device 700 also comprises a carrier 714, which supports the pre-filled syringe 712.
  • the carrier 714 comprises a deformable element 716 which takes the form of a flexible arm.
  • the flexible arm may be an extruded piece of the body of the carrier or a separate element, secured at one end to the body of the carrier 714.
  • the free end of the arm comprises a protrusion 718 directed towards the carrier 714.
  • Figure 7A shows the deformable element 716 in a first configuration in which it is engaged with a cooperating element of the needle cover 708.
  • the cooperating element may take the form of an aperture, a recess, a ridge or a frictional surface.
  • the deformable element 716 is configured to engage with the cooperating element while in the first configuration and thereby to provide a resistance to proximal movement of the needle cover 708 relative to the carrier 714 and body 710.
  • the cooperating element has the form of a slot and the deformable element is configured to abut an edge of the slot in the first configuration.
  • the protrusion 718 of the deformable element 716 may abut a proximally facing edge of the slot.
  • a distal facing edge of the protrusion 718 may be beveled, to allow the protrusion 718 to be forced radially inwards when the needle covers is pushed proximally.
  • the deformable element 716 has a stress concentrating region 720.
  • the stress concentrating region 720 may be located approximately half-way between the fixed and free ends of the flexible arm.
  • the stress concentrating region 720 may comprise a thinned or weakened area of the flexible arm.
  • the deformable element 716 may be in a relaxed state in the first configuration.
  • the carrier 714 may comprise two or more deformable elements 716.
  • two deformable elements 716 may be disposed opposite each other on the carrier 714 and may engage with corresponding slots in the needle cover 708.
  • Figure 7B shows the device 700 at the start of an activation movement.
  • a distal force is applied via the body 710 while the needle cover 708 is placed against the user’s skin, causing the needle cover 708 to move proximally into the device 700.
  • the needle cover 708 is in between the initial position and the activated position.
  • the deformable element 716 is deflected and exits the slot in the needle cover 708.
  • a normal force is exerted on the protrusion 718 which is forced radially inwards. This causes the flexible arm to bend downwards and be put under stress.
  • the stress in the stress concentrating region causes the deformable element 716 to break, as shown in Figure 7C. In this manner, movement of the needle cover 708 from the initial position to an intermediate position causes the deformable element 716 to be deformed from the first configuration to the second configuration.
  • the deformable element 716 has broken.
  • Figure 7C shows the device 700 in an activated state.
  • the deformable element 716 may be configured to break before the needle cover 708 reaches the activated position.
  • the deformable element 716 may break as soon as, or shortly after, the protrusion 718 of the flexible arm exits the slot in the needle cover 708.
  • the deformable element 716 may be configured to break entirely into two pieces.
  • the carrier 714 may have an aperture or recess underneath the deformable element 716 to allow room for the broken end piece of the deformable element 716 to be accommodated.
  • the deformable element 716 may produce a sound when deforming from the first configuration to the second configuration, for example a snapping sound. This may be used to provide feedback to a user or to a sensor within the device 700 or attached to the device 700.
  • the snap sound may be produced by the deformable element 716 itself when it breaks.
  • the deformable element 716 may be configured to produce a vibration when deforming from the first configuration to the second configuration. Again, this may be used to provide feedback to a user or to a sensor within the device 700 or attached to the device 700. The vibration may be produced by the deformable element 716 itself when breaking.
  • the deformable element 716 may be referred to as a permanently deformable element or irreversibly deformable element, since after the element is deformed, the deformation cannot be reversed. In this embodiment, after it is broken, the deformable element 716 does not exert a force on the needle cover for the remainder of its movement or during device removal. The activation force on the needle cover 708 required after the intermediate position is reached is therefore reduced compared to prior art devices. After the medicament has been delivered, during removal of the device 700, the movement of the needle cover 708 is reversed, but the deformable element 716 remains in its second configuration.
  • Figures 8A to 8D shows features of a third embodiment of a medicament delivery device 800, which is also referred to herein as an injector device. These Figures each show a cross section of the device 800 or a part of the device 800 during various stages of activation of the device.
  • the device has a distal end 802 and a proximal end 804.
  • the device 800 has a needle 806 for injecting medicament into a user at an injection site, a needle cover 808 and a body 810.
  • the body 810 is configured to be gripped by a user.
  • the body 810 forms part of the external surface of the device.
  • the device 800 houses a pre-filled syringe 812.
  • the needle 806 is in fluid communication with the pre-filled syringe 812 and extends from the distal end of the pre-filled syringe 812.
  • the needle cover 808 is axially movable relative to the body 810 between an initial position, shown in Figure 8A, in which the needle cover 808 covers the needle 806, and an activated position, shown in Figure 8C, for dispensing medicament from the device. In the activated position, the needle 806 protrudes from the distal end of the needle cover 808.
  • a spring may exert a spring force against the needle cover 808 which biases the needle cover axially, in the distal direction.
  • a force can be applied by a user against the force of the spring to move the needle cover 808 from the position shown in Figure 8A towards the position shown in Figure 8B.
  • Medicament is dispensed from the medicament delivery device 800 via the needle 806 while the needle cover 808 is in the activated position.
  • An automated mechanism is triggered to start the dispensing of medicament when the needle cover 808 reaches a predetermined axial position within the housing. The predetermined position is located just distally of the activated position.
  • the automated mechanism may comprise a plunger which is automatically released when the needle cover 808 reaches the predetermined axial position. When the plunger is released it moves within the pre-filled syringe to dispense medicament from the syringe through the needle 806.
  • the user removes a cap from the distal end of the medicament delivery device 800.
  • the user presses the needle cover 808 against an injection site to move the needle cover 808 axially relative to the body 810 and to uncover the needle 806.
  • the needle 806 is pushed into the injection site.
  • the automated mechanism is released, and medicament is automatically dispensed from the device via the needle 806.
  • the user holds the needle cover 808 in the activated position while the medicament is dispensed.
  • Figure 8A shows the device 800 in a pre-use state, which may also be called an initial state or initial position.
  • the needle cover 808 covers the needle 806 in this position.
  • the device 800 also comprises a carrier 814, which supports the pre-filled syringe 812.
  • the carrier 814 comprises a deformable element 816 which takes the form of a flexible arm.
  • the flexible arm may be an extruded piece of the body of the carrier or a separate element, secured at one end to the body of the carrier 814.
  • the free end of the arm comprises a protrusion 818 directed towards the carrier 814.
  • Figure 8A shows the deformable element 816 in a first configuration in which it is engaged with a cooperating element of the needle cover 808.
  • the cooperating element may take the form of an aperture, a recess, a ridge or a frictional surface.
  • the deformable element 816 is configured to engage with the cooperating element while in the first configuration and thereby to provide a resistance to proximal movement of the needle cover 808 relative to the carrier 814 and body 810.
  • the cooperating element has the form of a slot and the deformable element is configured to abut an edge of the slot in the first configuration.
  • the protrusion 818 of the deformable element 816 may abut a proximally facing edge of the slot.
  • a distal facing edge of the protrusion 818 may be beveled, to allow the protrusion 818 to be forced radially inwards when the needle covers is pushed proximally.
  • the carrier 814 also comprises a latching member 820.
  • the latching member 820 may comprise a flexible projection which extends distally form a portion of the carrier 814 and has a free end which contacts an underside or beveled end face of the deformable element 816, which may hold it in the first configuration.
  • the carrier 814 may comprise two or more deformable elements 816.
  • two deformable elements 816 may be disposed opposite each other on the carrier 814 and may engage with corresponding slots in the needle cover 808.
  • Figure 8C shows a close-up of the free end of the deformable element 816 and the latching member 820 in the first configuration.
  • Figure 8B shows the device 800 in an activated position. A distal force is applied via the body 810 while the needle cover 808 is placed against the user’s skin, causing the needle cover 808 to move proximally into the device 800. The needle cover 808 thus enters a position between the initial position and the activated position. During this initial movement, the deformable element 816 is deflected and exits the slot in the needle cover 808. In particular a normal force is exerted on the protrusion 818 which is forced radially inwards. This causes the flexible arm to bend downwards and to overcome the resisting force of the latching member 820.
  • the latching member 820 may bend downwards under the force exerted by the deformable element 816 until the free end of the latching member 820 clears the free end of the deformable element 816. At this point the latching member 820 snaps back up and abuts a top side of the deformable element 816. In this manner, movement of the needle cover 808 from the initial position to an intermediate position causes the deformable element 816 to be deformed from the first configuration to the second configuration.
  • Figure 8B shows the device 800 in an activated state.
  • the latching member 820 may be configured to clear the free end of the deformable element 816 before the needle cover 808 reaches the activated position.
  • latching member 820 may clear the free end of the deformable element 816 as soon as, or shortly after, the protrusion 818 of the flexible arm exits the slot in the needle cover 808.
  • the deformable element 816 may be in a relaxed state in the first configuration and a stressed state in the second configuration.
  • the latching member 820 may be biased downwards (towards the center axis of the device 800). It may therefore exert a force on the top side of the deformable element 816 to maintain it in the second configuration.
  • the deformable element 816 may be biased towards the second configuration.
  • the deformable element 816 is held in a stressed state by the latching member 820.
  • the latching member 820 may still exert some downward biasing force on the top side of the deformable element 816 in the second configuration to ensure that no element contacts the needle cover 808 for the remainder of the activation movement.
  • the carrier 814 may have an aperture or recess underneath the deformable element 816 to allow room for it to deform into the second configuration.
  • the deformable element 816 and/or the latching member 820 may produce a sound when the deformable element 816 deforms from the first configuration to the second configuration, for example a snapping sound. This may be used to provide feedback to a user or to a sensor within the device 800 or attached to the device 800.
  • the snap sound may be produced by the free end of the latching member 820 striking the protrusion 818 of the deformable element 816 or some other part of the free end of the deformable element 816.
  • the deformable element 816 may be configured to produce a vibration when deforming from the first configuration to the second configuration. Again, this may be used to provide feedback to a user or to a sensor within the device 800 or attached to the device 800.
  • the vibration may be produced by the free end of the latching member 820 striking the protrusion 818 of the deformable element 816 or some other part of the free end of the deformable element 816.
  • the deformable element 816 may be referred to as a permanently deformable element or irreversibly deformable element, since after the element is deformed, the deformation cannot be reversed.
  • the deformable element 816 is either biased towards the second configuration or is restrained in the second configuration by the latching member 820, or both. The activation force on the needle cover 808 required after the intermediate position is reached is therefore reduced compared to other devices.
  • Figure 8D shows a close-up of the free end of the deformable element 816 and the latching member 820 in the second configuration.
  • Figures 9A and 9B shows features of a fourth embodiment of a medicament delivery device 900, which is also referred to herein as an injector device. These Figures each show a cross section of a portion of a needle cover 908 and a carrier 914.
  • Figure 9A shows a close up of a portion of the carrier 914 with a deformable element 916 and the region of the needle cover 908 with which it interacts.
  • the other parts of the medicament delivery device 900 may be the same as those shown and described in the preceding embodiments.
  • Figure 9A shows the device 900 in a pre-use state, which may also be called an initial state or initial position.
  • the needle cover 908 covers the needle in this position.
  • the deformable element 916 takes the form of a flexible arm.
  • the flexible arm may be an extruded piece of the body of the carrier or a separate element, secured at one end to the body of the carrier 914.
  • the free end of the arm may comprise a shaped portion which may be slightly larger in cross section than the reminder of the flexible arm.
  • the needle cover 908 has at least one slot 922 and a ledge feature 920 located within the slot 922 or at one end of the slot.
  • Figure 9A shows the deformable element 916 in a first configuration in which it is engaged with the ledge feature 920 of the needle cover 908.
  • the deformable element 916 is in a flexed or stressed state and abuts an outward facing surface of the ledge feature 920.
  • a part of the deformable element 916 therefore protrudes through the slot 922 and beyond an external circumference of the needle cover 908.
  • a recess may be provided in the body of the medicament delivery device 900 to allow space for the free end of the deformable element 916 in the first configuration.
  • the body may also be shaped so as to have a larger diameter at this point.
  • the deformable element 916 is placed into the flexed first configuration during manufacture of the medicament delivery device 900 and remains in this state until the device is activated.
  • the carrier 914 may comprise two or more deformable elements 916.
  • two deformable elements 916 may be disposed opposite each other on the carrier 914 and may engage with corresponding ledge features 920 in the needle cover 908.
  • Figure 9B shows the device 900 with the deformable element 916 in a second configuration.
  • a distal force is applied via the body while the needle cover 908 is placed against the user’s skin, causing the needle cover 908 to move proximally into the device 900.
  • the needle cover 908 thus enters a position between the initial position and the activated position. During this initial movement, the deformable element 916 moves distally over the ledge feature 920. Due to the shaped portion at the free end of the flexible arm, the deformable element 916 may be further flexed radially outwards during this initial movement. Once the needle cover 908 reaches an intermediate position, the free end of the deformable element 916 clears the ledge feature 920 and drops through the slot 920, disengaging the carrier 914 from the needle cover 908. In this manner, movement of the needle cover 908 from the initial position to an intermediate position causes the deformable element 916 to be deformed from the first configuration to the second configuration.
  • the deformable element 916 is in a relaxed state in the second configuration.
  • the deformable element 916 may be referred to as a permanently deformable element or irreversibly deformable element, since in some examples after the element is deformed, the deformation cannot be reversed. In this embodiment, the deformable element 916 cannot be flexed so as to engage with the ledge feature 920.
  • the deformable element 916 remains in this second configuration for the remainder of the activation movement and throughout device removal. In this example, no part of the deformable element 916 is in contact with the needle cover 908 and thus the deformable element 916 does not exert any normal or friction force on the needle cover 908 in this position. The activation force on the needle cover 908 required after the intermediate position is reached is therefore reduced compared to prior art devices.
  • the deformable element 916 may produce a sound when it deforms from the first configuration to the second configuration, for example a snapping sound. This may be used to provide feedback to a user or to a sensor within the device 900 or attached to the device 900.
  • the snap sound may be produced by the free end of the deformable element 916 striking another component of the device 900 as it deforms.
  • the deformable element 916 may be configured to produce a vibration when deforming from the first configuration to the second configuration. Again, this may be used to provide feedback to a user or to a sensor within the device 900 or attached to the device 900. The vibration may be produced by the free end of the deformable element 916 striking another component of the device 900 as it deforms.
  • the movement of the needle cover 908 is reversed, but the deformable element 916 remains in its second configuration.
  • a force profile graph 1000 is shown illustrating the force profile of a first device 110 and a second device 500, 700, 800, 900.
  • the horizontal axis is the displacement of the needle cover is millimeters (mm) and the vertical axis is the user applied force in Newtons (N).
  • the first trace 1002 shows the force profile of the activation force of the first device 110 when the user is pushing the device 110 onto their body.
  • the second trace 1004 shows the force profile of the activation force of the medicament delivery device 500, 700, 800, 900, when the user is pushing the device onto their body.
  • the third trace 1006 shows the force profile of the device 110 when the user is removing the device 110 from their body.
  • the fourth trace 1008 shows the force profile of the medicament delivery device 500, 700, 800, 900, when the user is removing the device from their body.
  • First arrow 712 indicates the difference in activation force between the device 110 and the medicament delivery device 500during initial movement of the needle cover away from the pre-use position.
  • the lower activation force (of approx. 0.5N) is achieved by using a spring of lower force to bias the needle cover.
  • the force of the spring is chosen to overcome the frictional forces on the needle cover and cause it to return to the pre-use position when it is removed from the body.
  • a weaker spring can be used as the friction forces in the medicament delivery device 500 as reduced due to the presence of the second slots 602 and relaxed position of the resilient member 516 in the intermediate and activated positions.
  • Arrow 1010 indicates the difference in activation force between the device 110 and the medicament delivery device 500, 700, 800, 900during movement between the intermediate position (occurring at approximately the end of the initial force spike) and the activated position (maximum displacement of the needle cover).
  • the difference is approximately 1 N.
  • a spring is used to bias the needle cover in a distal direction relative to the carrier. The force of this spring is chosen to overcome the frictional forces on the needle cover and cause it to return to the pre-use position when it is removed from the body.
  • a weaker spring can be used. This may account for approximately half of the overall reduction in activation force required. The other half of the reduction is accounted for by the lack of friction forces between the carrier and the needle cover after the deformable element has transitioned to the second configuration.
  • the removal force profile of the medicament delivery device differs from that of the other device at the end of the removal movement, where the resilient member(s) 304 of the carrier 300 re-engage the slots 400 and cause a force spike.
  • This force spike is eliminated in the devices 500, 700, 800, 900 described above because the deformable element remains in the second configuration after the intermediate position during activation.
  • An active pharmaceutical ingredient (“API”) in the broadest terms, is a chemical structure that has a biological effect on humans or animals. In pharmacology, a drug or medicament is used in the treatment, cure, prevention, or diagnosis of disease or used to otherwise enhance physical or mental well-being. A drug or medicament may be used for a limited duration, or on a regular basis for chronic disorders.
  • a drug or medicament can include at least one API, or combinations thereof, in various types of formulations, for the treatment of one or more diseases.
  • API may include small molecules having a molecular weight of 500 Da or less; polypeptides, peptides and proteins (e.g., hormones, growth factors, antibodies, antibody fragments, and enzymes); carbohydrates and polysaccharides; and nucleic acids, double or single stranded DNA (including naked and cDNA), RNA, antisense nucleic acids such as antisense DNA and RNA, small interfering RNA (siRNA), ribozymes, genes, and oligonucleotides. Nucleic acids may be incorporated into molecular delivery systems such as vectors, plasmids, or liposomes. Mixtures of one or more drugs are also contemplated.
  • the drug or medicament may be contained in a primary package or “drug container” adapted for use with a drug delivery device.
  • the drug container may be, e.g., a cartridge, syringe, reservoir, or other solid or flexible vessel configured to provide a suitable chamber for storage (e.g., short- or long-term storage) of one or more drugs.
  • the chamber may be designed to store a drug for at least one day (e.g., 1 to at least 30 days).
  • the chamber may be designed to store a drug for about 1 month to about 2 years. Storage may occur at room temperature (e.g., about 20°C), or refrigerated temperatures (e.g., from about - 4°C to about 4°C).
  • the drug container may be or may include a dual-chamber cartridge configured to store two or more components of the pharmaceutical formulation to-be- administered (e.g., an API and a diluent, or two different drugs) separately, one in each chamber.
  • the two chambers of the dual-chamber cartridge may be configured to allow mixing between the two or more components prior to and/or during dispensing into the human or animal body.
  • the two chambers may be configured such that they are in fluid communication with each other (e.g., by way of a conduit between the two chambers) and allow mixing of the two components when desired by a user prior to dispensing.
  • the two chambers may be configured to allow mixing as the components are being dispensed into the human or animal body.
  • the drugs or medicaments contained in the drug delivery devices as described herein can be used for the treatment and/or prophylaxis of many different types of medical disorders.
  • disorders include, e.g., diabetes mellitus or complications associated with diabetes mellitus such as diabetic retinopathy, thromboembolism disorders such as deep vein or pulmonary thromboembolism.
  • Further examples of disorders are acute coronary syndrome (ACS), angina, myocardial infarction, cancer, macular degeneration, inflammation, hay fever, atherosclerosis and/or rheumatoid arthritis.
  • APIs and drugs are those as described in handbooks such as Rote Liste 2014, for example, without limitation, main groups 12 (anti-diabetic drugs) or 86 (oncology drugs), and Merck Index, 15 th edition.
  • APIs for the treatment and/or prophylaxis of type 1 or type 2 diabetes mellitus or complications associated with type 1 or type 2 diabetes mellitus include an insulin, e g., human insulin, or a human insulin analogue or derivative, a glucagon-like peptide (GLP-1), GLP-1 analogues or GLP-1 receptor agonists, or an analogue or derivative thereof, a dipeptidyl peptidase-4 (DPP4) inhibitor, or a pharmaceutically acceptable salt or solvate thereof, or any mixture thereof.
  • an insulin e g., human insulin, or a human insulin analogue or derivative
  • GLP-1 glucagon-like peptide
  • DPP4 dipeptidyl peptidase-4
  • analogue and “derivative” refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, by deleting and/or exchanging at least one amino acid residue occurring in the naturally occurring peptide and/or by adding at least one amino acid residue.
  • the added and/or exchanged amino acid residue can either be codable amino acid residues or other naturally occurring residues or purely synthetic amino acid residues.
  • Insulin analogues are also referred to as “insulin receptor ligands”.
  • the term ’’derivative refers to a polypeptide which has a molecular structure which formally can be derived from the structure of a naturally occurring peptide, for example that of human insulin, in which one or more organic substituent (e.g., a fatty acid) is bound to one or more of the amino acids.
  • one or more amino acids occurring in the naturally occurring peptide may have been deleted and/or replaced by other amino acids, including non-codeable amino acids, or amino acids, including non-codeable, have been added to the naturally occurring peptide.
  • insulin analogues examples include Gly(A21), Arg(B31), Arg(B32) human insulin (insulin glargine); Lys(B3), Glu(B29) human insulin (insulin glulisine); Lys(B28), Pro(B29) human insulin (insulin lispro); Asp(B28) human insulin (insulin aspart); human insulin, wherein proline in position B28 is replaced by Asp, Lys, Leu, Vai or Ala and wherein in position B29 Lys may be replaced by Pro; Ala(B26) human insulin; Des(B28-B30) human insulin; Des(B27) human insulin and Des(B30) human insulin.
  • insulin derivatives are, for example, B29-N-myristoyl-des(B30) human insulin, Lys(B29) (N- tetradecanoyl)-des(B30) human insulin (insulin detemir, Levemir®); B29-N-palmitoyl-des(B30) human insulin; B29-N-myristoyl human insulin; B29-N-palmitoyl human insulin; B28-N-myristoyl LysB28ProB29 human insulin; B28-N-palmitoyl- LysB28ProB29 human insulin; B30-N-myristoyl-ThrB29LysB30 human insulin; B30-N- palmitoyl- ThrB29LysB30 human insulin; B29-N-(N-palmitoyl-gamma-glutamyl)-des(B30) human insulin, B29-N-omega-carboxypentadecanoyl-gamma-L-g
  • GLP-1 , GLP-1 analogues and GLP-1 receptor agonists are, for example, Lixisenatide (Lyxumia®), Exenatide (Exendin-4, Byetta®, Bydureon®, a 39 amino acid peptide which is produced by the salivary glands of the Gila monster), Liraglutide (Victoza®), Semaglutide, Taspoglutide, Albiglutide (Syncria®), Dulaglutide (Trulicity®), rExendin-4, CJC-1134-PC, PB-1023, TTP-054, Langlenatide / HM-11260C (Efpeglenatide), HM-15211 , CM-3, GLP-1 Eligen, GRMD-0901, NN-9423, NN-9709, NN- 9924, NN-9926, NN-9927, Nodexen, Viador-GLP-1 , CVX-096, ZYOG-1 , ZYD-1 , GLP
  • oligonucleotide is, for example: mipomersen sodium (kynamro®), a cholesterol-reducing antisense therapeutic for the treatment of familial hypercholesterolemia or RG012 for the treatment of Alport 28yndrome.
  • DPP4 inhibitors are Linagliptin, Vildagliptin, Sitagliptin, Denagliptin, Saxagliptin, Berberine.
  • hormones include hypophysis hormones or hypothalamus hormones or regulatory active peptides and their antagonists, such as Gonadotropine (Follitropin, Lutropin, Choriongonadotropin, Menotropin), Somatropine (Somatropin), Desmopressin, Terlipressin, Gonadorelin, Triptorelin, Leuprorelin, Buserelin, Nafarelin, and Goserelin.
  • polysaccharides include a glucosaminoglycane, a hyaluronic acid, a heparin, a low molecular weight heparin or an ultra-low molecular weight heparin or a derivative thereof, or a sulphated polysaccharide, e.g. a poly-sulphated form of the above-mentioned polysaccharides, and/or a pharmaceutically acceptable salt thereof.
  • a pharmaceutically acceptable salt of a poly-sulphated low molecular weight heparin is enoxaparin sodium.
  • An example of a hyaluronic acid derivative is Hylan G-F 20 (Synvisc®), a sodium hyaluronate.
  • antibody refers to an immunoglobulin molecule or an antigenbinding portion thereof.
  • antigen-binding portions of immunoglobulin molecules include F(ab) and F(ab’)2 fragments, which retain the ability to bind antigen.
  • the antibody can be polyclonal, monoclonal, recombinant, chimeric, de-immunized or humanized, fully human, non-human, (e.g., murine), or single chain antibody.
  • the antibody has effector function and can fix complement.
  • the antibody has reduced or no ability to bind an Fc receptor.
  • the antibody can be an isotype or subtype, an antibody fragment or mutant, which does not support binding to an Fc receptor, e.g., it has a mutagenized or deleted Fc receptor binding region.
  • the term antibody also includes an antigen-binding molecule based on tetravalent bispecific tandem immunoglobulins (TBTI) and/or a dual variable region antibody-like binding protein having cross-over binding region orientation (CODV).
  • TBTI tetravalent bispecific tandem immunoglobulins
  • CODV cross-over binding region orientation
  • fragment refers to a polypeptide derived from an antibody polypeptide molecule (e.g., an antibody heavy and/or light chain polypeptide) that does not comprise a full-length antibody polypeptide, but that still comprises at least a portion of a full-length antibody polypeptide that is capable of binding to an antigen.
  • Antibody fragments can comprise a cleaved portion of a full length antibody polypeptide, although the term is not limited to such cleaved fragments.
  • Antibody fragments that are useful in the devices and methods disclosed herein include, for example, Fab fragments, F(ab’)2 fragments, scFv (single-chain Fv) fragments, linear antibodies, monospecific or multispecific antibody fragments such as bispecific, trispecific, tetraspecific and multispecific antibodies (e.g., diabodies, triabodies, tetrabodies), monovalent or multivalent antibody fragments such as bivalent, trivalent, tetravalent and multivalent antibodies, minibodies, chelating recombinant antibodies, tribodies or bibodies, intrabodies, nanobodies, small modular immunopharmaceuticals (SMIP), binding-domain immunoglobulin fusion proteins, camelized antibodies, and VHH containing antibodies. Additional examples of antigen-binding antibody fragments are known in the art.
  • SMIP small modular immunopharmaceuticals
  • CDR complementarity-determining region
  • framework region refers to amino acid sequences within the variable region of both heavy and light chain polypeptides that are not CDR sequences, and are primarily responsible for maintaining correct positioning of the CDR sequences to permit antigen binding.
  • framework regions themselves typically do not directly participate in antigen binding, as is known in the art, certain residues within the framework regions of certain antibodies can directly participate in antigen binding or can affect the ability of one or more amino acids in CDRs to interact with antigen.
  • antibodies are anti PCSK-9 mAb (e.g., Alirocumab), anti IL-6 mAb (e.g., Sarilumab), and anti IL-4 mAb (e.g., Dupilumab).
  • PCSK-9 mAb e.g., Alirocumab
  • anti IL-6 mAb e.g., Sarilumab
  • anti IL-4 mAb e.g., Dupilumab
  • Pharmaceutically acceptable salts of any API described herein are also contemplated for use in a drug or medicament in a drug delivery device.
  • Pharmaceutically acceptable salts are for example acid addition salts and basic salts.
  • An example drug delivery device may involve a needle-based injection system as described in Table 1 of section 5.2 of ISO 11608-1 :2014 €. As described in ISO 11608- 1 :2014(E), needle-based injection systems may be broadly distinguished into multi-dose container systems and single-dose (with partial or full evacuation) container systems.
  • the container may be a replaceable container or an integrated non-replaceable container.
  • a multi-dose container system may involve a needle-based injection device with a replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user).
  • Another multi-dose container system may involve a needle-based injection device with an integrated non-replaceable container. In such a system, each container holds multiple doses, the size of which may be fixed or variable (pre-set by the user).
  • a single-dose container system may involve a needle-based injection device with a replaceable container.
  • each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation).
  • each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation).
  • a single-dose container system may involve a needlebased injection device with an integrated non-replaceable container.
  • each container holds a single dose, whereby the entire deliverable volume is expelled (full evacuation).
  • each container holds a single dose, whereby a portion of the deliverable volume is expelled (partial evacuation).

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Environmental & Geological Engineering (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)

Abstract

Un dispositif d'administration de médicament pour réduire une force requise pour activer le dispositif comprend une aiguille disposée au niveau d'une extrémité distale du dispositif, un couvercle d'aiguille et un corps. Le couvercle d'aiguille est mobile axialement par rapport au corps entre une position initiale dans laquelle le couvercle d'aiguille recouvre l'aiguille et une position activée pour distribuer un médicament. L'aiguille fait saillie à partir de l'extrémité distale du couvercle d'aiguille lorsque le couvercle d'aiguille est dans la position activée. Le dispositif d'administration de médicament comprend un support conçu pour supporter une seringue. Le support est disposé à l'intérieur du couvercle d'aiguille et comprend un élément déformable conçu pour passer d'une première configuration dans laquelle l'élément déformable est en prise avec le couvercle d'aiguille à une seconde configuration dans laquelle l'élément déformable n'est pas en prise avec le couvercle d'aiguille.
PCT/US2025/018089 2024-03-04 2025-03-03 Dispositif injecteur Pending WO2025188598A1 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18/594,643 US12274874B1 (en) 2024-03-04 2024-03-04 Injector device
EP24161240.7 2024-03-04
EP24161240 2024-03-04
US18/594,643 2024-03-04

Publications (2)

Publication Number Publication Date
WO2025188598A1 true WO2025188598A1 (fr) 2025-09-12
WO2025188598A8 WO2025188598A8 (fr) 2025-10-02

Family

ID=95250893

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2025/018089 Pending WO2025188598A1 (fr) 2024-03-04 2025-03-03 Dispositif injecteur

Country Status (1)

Country Link
WO (1) WO2025188598A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112310A1 (en) * 2003-07-31 2007-05-17 Sid Technologies Llc Injecting apparatus
US20170106146A1 (en) * 2014-07-01 2017-04-20 Amgen Inc. Autoinjector with Low Energy Plunger Loading
US20190358400A1 (en) * 2013-11-03 2019-11-28 Terumo Kabushiki Kaisha Syringe with needle, prefilled syringe, and medical liquid administration tool using the same
US20200046909A1 (en) * 2003-12-18 2020-02-13 Tecpharma Licensing Ag Auto-injector with active agent container latching
US20200289754A1 (en) * 2017-10-30 2020-09-17 Sanofi Injector Device

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070112310A1 (en) * 2003-07-31 2007-05-17 Sid Technologies Llc Injecting apparatus
US20200046909A1 (en) * 2003-12-18 2020-02-13 Tecpharma Licensing Ag Auto-injector with active agent container latching
US20190358400A1 (en) * 2013-11-03 2019-11-28 Terumo Kabushiki Kaisha Syringe with needle, prefilled syringe, and medical liquid administration tool using the same
US20170106146A1 (en) * 2014-07-01 2017-04-20 Amgen Inc. Autoinjector with Low Energy Plunger Loading
US20200289754A1 (en) * 2017-10-30 2020-09-17 Sanofi Injector Device

Also Published As

Publication number Publication date
WO2025188598A8 (fr) 2025-10-02

Similar Documents

Publication Publication Date Title
US20230277777A1 (en) Drug Delivery Device
US11400232B2 (en) Drug delivery device
US11406761B2 (en) Injector device
JP7611698B2 (ja) プランジャおよび薬物送達デバイス
US11351304B2 (en) Injection device
EP3492124A1 (fr) Dispositif d'injecteur
US20250018129A1 (en) Injection Device
US11364345B2 (en) Medicament injector device
US12337160B1 (en) Medicament delivery device
US12274874B1 (en) Injector device
US12274873B1 (en) Medicament delivery device
US12268858B1 (en) Injector device
WO2025188598A1 (fr) Dispositif injecteur
US12303675B1 (en) Medicament delivery device
US12337159B1 (en) Medicament delivery device
US12403266B1 (en) Medicament delivery device
EP3860694A1 (fr) Capuchon
WO2025188594A1 (fr) Dispositif injecteur
WO2025188595A1 (fr) Dispositif d'administration de médicament
WO2025132563A1 (fr) Dispositif d'injection
WO2025221656A1 (fr) Dispositif d'administration de médicament
WO2025188599A1 (fr) Dispositif d'administration de médicament
HK40055623B (en) An injection device
HK40055623A (en) An injection device
HK40008382A (en) Injection device

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 25716235

Country of ref document: EP

Kind code of ref document: A1